Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MHC-related protein 1–restricted recognition of cancer via a semi-invariant TCR-α chain
Garry Dolton, … , Barbara Szomolay, Andrew K. Sewell
Garry Dolton, … , Barbara Szomolay, Andrew K. Sewell
Published January 2, 2025
Citation Information: J Clin Invest. 2025;135(1):e181895. https://doi.org/10.1172/JCI181895.
View: Text | PDF
Research Article Immunology Oncology

MHC-related protein 1–restricted recognition of cancer via a semi-invariant TCR-α chain

  • Text
  • PDF
Abstract

The T cell antigen presentation platform MR1 consists of 6 allomorphs in humans that differ by no more than 5 amino acids. The principal function of this highly conserved molecule involves presenting microbial metabolites to the abundant mucosal-associated invariant T (MAIT) cell subset. Recent developments suggest that the role of MR1 extends to presenting antigens from cancer cells, a function dependent on the K43 residue in the MR1 antigen binding cleft. Here, we successfully cultured cancer-activated, MR1-restricted T cells from multiple donors and confirmed that they recognized a wide range of cancer types expressing the most common MR1*01 and/or MR1*02 allomorphs (over 95% of the population), while remaining inert to healthy cells including healthy B cells and monocytes. Curiously, in all but one donor these T cells were found to incorporate a conserved TCR-α chain motif, CAXYGGSQGNLIF (where X represents 3–5 amino acids), because of pairing between 10 different TRAV genes and the TRAJ42 gene segment. This semi-invariance in the TCR-α chain is reminiscent of MAIT cells and suggests recognition of a conserved antigen bound to K43.

Authors

Garry Dolton, Hannah Thomas, Li Rong Tan, Cristina Rius Rafael, Stephanie Doetsch, Giulia-Andreea Ionescu, Lucia F. Cardo, Michael D. Crowther, Enas Behiry, Théo Morin, Marine E. Caillaud, Devinder Srai, Lucia Parolini, Md Samiul Hasan, Anna Fuller, Katie Topley, Aaron Wall, Jade R. Hopkins, Nader Omidvar, Caroline Alvares, Joanna Zabkiewicz, John Frater, Barbara Szomolay, Andrew K. Sewell

×

Figure 3

Phenotypic and clonotypic analysis of MR1-restricted cancer-reactive T cells.

Options: View larger image (or click on image) Download as PowerPoint
Phenotypic and clonotypic analysis of MR1-restricted cancer-reactive T c...
(A) CD8- and CD4-coreceptor phenotyping of MR1-reactive T cell lines from donors 0–6 and ME216. T cells from ME216 were preenriched with CD8 beads and therefore would not be CD4+ or CD4/CD8 double negative. (B) CD161 staining index (fold increase of CD161 staining relative to fluorescence minus 1 control) of 6 MR1-reactive T cell lines. MC.7.G5 and MC.27.759S clones included, as well as a MAIT and CD8+ T cell line. (C) TRAV and TRAJ gene usage of MR1-reactive T cells from 6 healthy donors and AML patient ME216. Circos plots show TRAV (V) genes on the left and TRAJ (J) genes on the right, with the size of the outer arcs corresponding to the relative frequency of the TRAV or TRAJ genes. The ribbons between the arcs represent TRAV-TRAJ pairings. (D) CDR3 logo plot for TCRs containing TRAJ42 with CDR3s of 17 amino acids in length from this figure and Supplemental Figure 5, giving the CAXYGGSQGNLIF motif (where X represents 5 amino acids). (E) TRAJ42 (preserved tyrosine with and without asparagine) summary of TCRs for donors in this figure and from the VDJdb database.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts